



[Go to Product page](#)

Datasheet for ABIN2666727
IL36A/IL1F6 Protein (AA 8-160)

Overview

Quantity:	10 µg
Target:	IL36A/IL1F6 (IL1F6)
Protein Characteristics:	AA 8-160
Origin:	Mouse
Source:	Escherichia coli (E. coli)
Protein Type:	Recombinant
Biological Activity:	Active
Application:	Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)

Product Details

Purity:	> 95 % , as determined by Coomassie stained SDS-PAGE.
Sterility:	0.22 µm filtered
Endotoxin Level:	Less than 0.01 ng per µg cytokine as determined by the LAL method.

Target Details

Target:	IL36A/IL1F6 (IL1F6)
Alternative Name:	IL-36 alpha (IL1F6 Products)
Background:	IL-36α is one of the IL-36 cytokines that are part of the IL-1 family. Like other IL-1 family members, IL-36α requires N-terminal processing to gain full bioactivity. IL-36α signals through IL-36R/IL-1RAcP, which results in MAPK, Erk1/2, and JNK activation. IL-36α is implicated in skin homeostasis, and is overexpressed in psoriatic lesional skin. Transgenic mice overexpressing

Target Details

IL-36 α in their skin have an inflammatory skin condition showing some characteristics of human psoriasis, including thickened scaly skin, acanthosis, hyperkeratosis, and dermis infiltration. EGF regulates expression of IL-36 α in skin cells. IL-36 α can also be detected in adipose tissue where it reduces adipocyte differentiation and also induces inflammatory gene expression in mature adipocytes. In lungs, the expression of IL-36 α is increased in response to inflammatory stimuli. Intratracheal instillation of recombinant mouse IL-36 α induces CXCL1 and CXCL2 expression and also neutrophil influx in the lungs. IL-36 α , IL-36 β , and IL-36 γ induce in vitro expression of RNAs of multiple cytokines (IL-6, IL-12 p40, CXCL1, CCL1, IL-12 p35, IL-1 β , IL-19 p19, GM-CSF, CXCL10, TNF α , CCL3, VCAM-1, and ICAM-1) in mouse bone marrow-derived dendritic cells and CD4 T cells obtained from normal mice. IL-36 α expression is elevated in chronic kidney disease and in rheumatoid arthritis synovium, and decreased expression correlates with a poor prognosis in hepatocellular carcinomas.

Molecular Weight: The 153 amino acid recombinant protein has a predicted molecular mass of approximately 17 kDa. The DTT-reduced and non-reduced protein migrate at approximately 17 kDa by SDS-PAGE. The predicted N-terminal amino acid is Arg.

Pathways: [Cancer Immune Checkpoints](#)

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment: Biological activity: The activity is determined by the dose-dependent stimulation of IL-6 secretion in 3T3L1 preadipocytes. The ED50 is 2 - 10 ng/ml, corresponding to a specific activity 1 - 5 x 10⁵ units/mg.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions can also be prepared at 50 - 100 μ g/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 $^{\circ}$ C to -70 $^{\circ}$ C.

Buffer: 0.22 μ m filtered protein solution is in 20 mM Hepes, pH 7.2, 150 mM NaCl, 10 mM TCEP.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 $^{\circ}$ C

Handling

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one week, at -20°C for six months, or at -70°C for one year.